Neuropace Stock Investor Sentiment

NPCE Stock  USD 10.37  0.60  5.47%   
About 55% of Neuropace's investor base is interested to short. The analysis of overall sentiment of trading Neuropace stock suggests that many investors are impartial at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.

Comfort Level 45

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Neuropace's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Neuropace.

Neuropace Historical Sentiment

Although Neuropace's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Neuropace, such as negative comments on social media and news outlets, may cause fear in the market and push Neuropace's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Neuropace.
  

Neuropace Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neuropace Historical Investor Sentiment

Investor biases related to Neuropace's public news can be used to forecast risks associated with an investment in Neuropace. The trend in average sentiment can be used to explain how an investor holding Neuropace can time the market purely based on public headlines and social activities around Neuropace. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuropace's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuropace and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neuropace news discussions. The higher the estimate score, the more favorable the investor's outlook on Neuropace.
few days ago at simplywall.st         
NeuroPace, Inc. Annual Results Heres What Analysts Are Forecasting For This Year
Simply Wall St News at Macroaxis
few days ago at thelincolnianonline.com         
Cantor Fitzgerald Predicts Higher Earnings for NeuroPace
news
few days ago at thelincolnianonline.com         
Disposition of 1334 shares by Martha Morrell of Neuropace at 7. subject to Rule 16b-3
news
six days ago at finance.yahoo.com         
NeuroPace Full Year 2024 Earnings EPS Beats Expectations
Yahoo News
over a week ago at gurufocus.com         
Q4 2024 Neuropace Inc Earnings Call Transcript
Gurufocus Stories at Macroaxis
over a week ago at insidermonkey.com         
NeuroPace, Inc. Q4 2024 Earnings Call Transcript
insidermonkey News
over a week ago at gurufocus.com         
NeuroPace Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and Strategic ...
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
NeuroPace Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and Strategic ...
Yahoo News
over a week ago at gurufocus.com         
NeuroPace Inc Q4 2024 Earnings EPS Loss of 0. ...
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
UPDATE NeuroPace to Present at the Leerink Partners Global Healthcare Conference
Yahoo News
over a week ago at gurufocus.com         
UPDATE -- NeuroPace to Present at the Leerink Partners Global Healthcare Conference
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
NeuroPace Inc. Q4 Earnings Snapshot
Yahoo News
over a week ago at gurufocus.com         
NeuroPace Inc Q4 2024 Earnings Report Preview What to Look For
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Disposition of 1337 shares by Rebecca Kuhn of Neuropace at 11.81 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.

Neuropace Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
01/06/2025
2
Institutions profited after NeuroPace, Inc.s market cap rose US37m last week but private equity firms profited the most
01/08/2025
3
Disposition of 3200 shares by Martha Morrell of Neuropace at 15.01 subject to Rule 16b-3
01/24/2025
4
Disposition of 200 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3
01/30/2025
5
Morgan Stanley Reduces Stake in NeuroPace Inc A Strategic Portfolio Adjustment
02/04/2025
6
Disposition of 5270845 shares by Kck Ltd. of Neuropace at 9.4 subject to Rule 16b-3
02/20/2025
7
Disposition of 78334 shares by Martha Morrell of Neuropace at 13.7213 subject to Rule 16b-3
02/21/2025
8
Disposition of 926 shares by Martha Morrell of Neuropace at 8.32 subject to Rule 16b-3
02/25/2025
9
Rapid Micro Biosystems, Inc. Reports Q4 Loss, Tops Revenue Estimates
02/28/2025
10
NeuroPace Inc Q4 2024 Earnings Report Preview What to Look For
03/03/2025
11
UPDATE -- NeuroPace to Present at the Leerink Partners Global Healthcare Conference
03/04/2025
12
NeuroPace Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and Strategic ...
03/05/2025
13
NeuroPace Full Year 2024 Earnings EPS Beats Expectations
03/06/2025
14
NeuroPace, Inc. Annual Results Heres What Analysts Are Forecasting For This Year
03/07/2025

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.